Inhibition of DNA topoisomerase II may trigger illegitimate recombination in living cells: Experiments with a model system

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 598-608

  Umanskaya, Olga N ^a   Lebedeva, Svetlana S ^a,b   Gavrilov, Alexey A ^a,b   Bystritskiy, Andrey A ^a   Razin, Sergey V ^a,b  

^a INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Chromosomal rearrangements; DNA topoisomerase II; Illegitimate recombination

Indexed keywords

AMPICILLIN; DNA TOPOISOMERASE (ATP HYDROLYSING); TENIPOSIDE;

ANIMAL CELL; ARTICLE; BACTERIAL CELL; CCDB GENE; CELL STRAIN COS1; CONTROLLED STUDY; DNA FLANKING REGION; DNA STRAND BREAKAGE; DRUG TARGETING; ENZYME INHIBITOR INTERACTION; ESCHERICHIA COLI; GENE CONSTRUCT; GENE INDUCTION; GENETIC RECOMBINATION; GENETIC TRANSFECTION; IN VITRO STUDY; MAMMAL CELL; MARKER GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; ESCHERICHIA COLI; GENE REARRANGEMENT; GENES, BACTERIAL; HUMANS; MODELS, GENETIC; NUCLEOSOMES; PLASMIDS; RECOMBINATION, GENETIC; TRANSFORMATION, GENETIC;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 33748931594     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20938     Document Type: Article

References (53)

1. Adachi Y, Kas E, Laemmli UK. 1989. Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J 8(13):3997-4006.
2. Adachi N, Suzuki H, Iiizumi S, Koyama H. 2003. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: Implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278:35897-35902.
3. Adachi N, Iiizumi S, So S, Koyama H. 2004. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. Biochem Biophys Res Commun 318:856-861.
4. Asami Y, Jia DW, Tatebayashi K, Yamagata K, Tanokura M, Ikeda H. 2002. Effect of the DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast chromosomes. Gene 291:251-257.
5. Bae YS, Kawasaki I, Ikeda H, Liu LF. 1988. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 85:2076-80.
6. Bernard P. 1995. New ccdB positive-selection cloning vectors with kanamycin or chloramphenicol selectable markers. Gene 162:159-160.
7. Bernard P, Gabant P, Bahassi EM, Couturier M. 1994. Positive-selection vectors using the F plasmid ccdB killer gene. Gene 148:71-74.
8. Berrios M, Osheroff N, Fisher PA. 1985. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82:4142-4146.
9. Bode J, Schlake T, Rios-Ramirez M, Mielke C, Stengert M, Kay V, Klehr-Wirth D. 1995. Scaffold/matrix-attached regions: Structural properties creating transcriptionally active loci. Int Rev Cytol 162A:389-454.
10. Boulikas T. 1993. Nature of DNA sequences at the attachment regions of genes to the nuclear matrix. J Cell Biochem 52:14-22.
11. Boulikas T. 1994. Transcription factor binding sites in the matrix attachment region (MAR) of the chicken alphaglobin gene. J Cell Biochem 55:513-529.
12. Bystritskiy AA, Razin SV. 2004. Breakpoint clusters: Reason or consequence? Crit Rev Eukaryot Gene Expr 14:65-77.
13. Champoux James J. 2001. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 70:369-413.
14. Charron M, Hancock R. 1991. Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26. Chromosoma 100:97-102.
15. Cockerill PN, Garrard WT. 1986. Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites. Cell 44(2):273-282.
16. Cook PR, Brazell IA, Jost E. 1976. Characterization of nuclear structures containing superhelical DNA. J Cell Sci 22:303-324.
17. Elliott B, Jasin M. 2002. Double-strand breaks and translocations in cancer. Cell Mol Life Sci 59:373-385.
18. Felix CA. 1998. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400 (1-3):233-255.
19. Felsenfeld G, Burgess-Beusse B, Farrell C, Gaszner M, Ghirlando R, Huang S, Jin C, Litt M, Magdinier F, Mutskov V, Nakatani Y, Hadami H, West A, Yusufzai T. 2004. Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol 69:245-250.
20. Fortune JM, Osheroff N. 2000. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253.
21. Gale KC, Osheroff N. 1992. Intrinsic intermolecular DNA ligation activity of eukaryotic topoisomerase II. Potential roles in recombination. J Biol Chem 267: 12090-12097.
22. Gasser SM, Laemmli UK. 1986. Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster. Cell 46:521-530.
23. Hart SS, Foroni L. 2002. Core binding factor genes and human leukemia. Haematologica 87:1307-1323.
24. Hirt B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26:365-369.
25. Holmes-Davis R, Comai L. 2002. The matrix attachment regions (MARs) associated with the heat shock cognate 80 gene (HSC80) of tomato represent specific regulatory elements. Mol Genet Genomics 266:891-898.
26. Ikeda H. 1994. DNA topoisomerase-mediated illegitimate recombination. Adv Pharmacol 29A:147-165.
27. Ikeda H, Moriya K, Matsumoto T. 1981. In vitro study of illegitimate recombination: Involvement of DNA gyrase. Cold Spring Harb Symp Quant Biol 45(1):399-408.
28. Jaeger U, Karth GD, Knapp S, Friedl J, Laczika K, Kusec R. 1994. Molecular mechanism of the t(14;18)-a model for lymphoid-specific chromosomal translocations. Leuk Lymphoma 14:197-202.
29. Kantidze OL, Iarovaia OV, Razin SV. 2006. Assembly of nuclear matrix-bound protein complexes involved in non-homologous end joining is induced by inhibition of DNA-topoisomerase II. J Cell Physol (in press).
30. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. 2001. Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma 41:255-276.
31. Li T-K, Liu LF. 2001. Tumor cell death induced by topoisomerase-targeting drugs. Ann Rev Pharmacol Toxicol 41:53-77.
32. Liu LF. 1989. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
33. Mao Y, Desai SD, Liu LF. 2000. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 275(34):26066-26073.
34. McWhinney C, Leffak M. 1990. Autonomous replication of a DNA fragment containing the chromosomal replication origin of the human c-myc gene. Nucleic Acids Res 18: 1233-1242.
35. Mitelman F. 2000. Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253.
36. Mitelman F, Johansson B, Mertens F. 2003. Mitelman Database of Chromosome Aberrations in Cancer [Web Page]. Available at http://cgap.nci.nih.gov/ Chromosomes/Mitelman.
37. Nitiss JL, Wang JC. 1996. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50(5):1095-1102.
38. Ohira M, Ootsuyama A, Suzuki E, Ichikawa H, Seki N, Nagase T, Nomura N, Ohki M. 1996. Identification of a novel human gene containing the tetratricopeptide repeat domain from the Down syndrome region of chromosome 21. DNA Res 3(1):9-16.
39. Okuda T, Nishimura M, Nakao M, Fujita Y. 2001. RUNX1/AML1: A central player in hematopoiesis. Int J Hematol 74:252-257.
40. Osoegawa K, Mammoser AG, Wu C, Frengen E, Zeng C, Catanese JJ, de Jong PJ. 2001. A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res 11(3):483-496.
41. Porter SD, Hu J, Gilks CB. 1999. Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. Dev Genet 25:40-48.
42. Ratain MJ, Rowley JD. 1992. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes. Ann Oncol 3(2):107-111.
43. Razin SV. 2001. The nuclear matrix and chromosomal DNA loops: Is there any correlation between partitioning of the genome into loops and functional domains. Cell Mol Biol Lett 6:59-69.
44. Razin S, Gromova I. 1995. The channels model of nuclear matrix structure. Bioessays 17(5):443-450.
45. Rowley JD. 1993. Rearrangements involving chromosome band 11Q23 in acute leukaemia. Semin Cancer Biol 4: 377-385.
46. Rowley JD. 1999. The role of chromosome translocations in leukemogenesis. Semin Hematol 36:59-72.
47. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, et al. 1997. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90:535-541.
48. Tsukahara F, Hattori M, Muraki T, Sakaki Y. 1996. Identification and cloning of a novel cDNA belonging to tetratricopeptide repeat gene family from Down syndrome-critical region 21q22.2. J Biochem (Tokyo) 120(4): 820-827.
49. Wang JC. 2002. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev: Mol Cell Biol 3:430-440.
50. Welzel N, Le T, Marculescu R, Mitterbauer G, Chott A, Pott C, Kneba M, Du MQ, Kusec R, Drach J, Raderer M, Mannhalter C, Lechner K, Nadel B, Jaeger U. 2001. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: Implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 61:1629-1636.
51. Yan ZJ, Qian RL. 1998. The 5′-flanking cis-acting elements of the human epsilon-globin gene associates with the nuclear matrix and binds to the nuclear matrix proteins. Cell Res 8:209-218.
52. Yusufzai TM, Felsenfeld G. 2004. The 5′-HS4 chicken betaglobin insulator is a CTCF-dependent nuclear matrix-associated element. Proc Natl Acad Sci USA 101:8620-8624.
53. Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le Beau MM, Larson RA, Rowley JD. 2002. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci USA 99: 3070-3075.